MedTrace Logo

Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies

NCT04515108 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2020-08-17

No results posted yet for this study

Summary

Complete blood count parameters are routinely evaluated cost-effective markers in diagnosis and clinical follow-up of infectious diseases.There is increasing number of studies to report the course of COVID-19 in pregnancy. The current study aimed to elucidate the changes in hematologic parameters in response to SARS-CoV-2 infection and whether there was an increase in adverse perinatal outcomes such as increased neonatal intensive care unit admission and lower APGAR scores in pregnancies with COVID-19.

Conditions

  • Pregnancy, Infections in
  • Covid19

Interventions

OTHER

Clinical assessment

Perinatal outcomes and diagnostic value of hematologic parameters were compared between pregnancies with and without COVID-19.

Sponsors & Collaborators

  • Ankara City Hospital Bilkent

    lead OTHER

Principal Investigators

  • Esin Merve Erol Koç, MD · Ankara City Hospital Bilkent

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-10
Primary Completion
2020-08-05
Completion
2020-08-10

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04515108 on ClinicalTrials.gov